Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Receivables: 2011-2025

Historic Change in Receivables for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to $40.5 million.

  • Catalyst Pharmaceuticals' Change in Receivables rose 3606.22% to $40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year increase of 371.20%. This contributed to the annual value of $12.0 million for FY2024, which is 72.23% down from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Change in Receivables is $40.5 million, which was up 850.57% from -$5.4 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Change in Receivables' 5-year high stood at $40.5 million during Q3 2025, with a 5-year trough of -$5.4 million in Q2 2025.
  • For the 3-year period, Catalyst Pharmaceuticals' Change in Receivables averaged around $8.7 million, with its median value being $5.8 million (2025).
  • The largest annual percentage gain for Catalyst Pharmaceuticals' Change in Receivables in the last 5 years was 18,466.67% (2022), contrasted with its biggest fall of 239.65% (2022).
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Change in Receivables stood at -$6,000 in 2021, then skyrocketed by 18,466.67% to $1.1 million in 2022, then spiked by 395.92% to $5.5 million in 2023, then skyrocketed by 31.93% to $7.2 million in 2024, then skyrocketed by 3,606.22% to $40.5 million in 2025.
  • Its Change in Receivables was $40.5 million in Q3 2025, compared to -$5.4 million in Q2 2025 and $5.8 million in Q1 2025.